Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suraxavir Marboxil and Oseltamivir for Influenza Prophylaxis
NCT07236814Phase 3Recruiting
- Sponsor
- Capital Medical University
- Start
- Nov 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of suraxavir marboxil in influenza (3 arms), sponsored by Capital Medical University. Primary endpoint: Proportion of room contacts who develop clinical influenza at 5 days. Started Nov 2025; status: recruiting.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07236814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236814.